CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03860272
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:06.384708+00:00
Published At: 2026-03-30T00:00:00+00:00
Record Updated At: 2026-03-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Cancer", "Angiosarcoma", "Colorectal Cancer Without Liver Metastases", "Endometrial Cancer", "Fibrolamellar Carcinoma", "Non-small-cell Lung Cancer", "Ovarian Cancer", "Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-30"
protocolSection.identificationModule.nctId: "NCT03860272"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.